Sherene Loi
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Cancer Research top 0.02%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 230
- Cancer Immunotherapy and Biomarkers 119
- HER2/EGFR in Cancer Research 80
- Cancer Cells and Metastasis 26
- Cancer Research 103
- Breast Cancer Treatment Studies 60
- Cancer Genomics and Diagnostics 50
- Co-authors
- Christos P. Sotiriou (62 shared papers)Martine J Piccart (51 shared papers)Hiroji Iwata (25 shared papers)Roberto Salgado (48 shared papers)Peter Savas (39 shared papers)Seock‐Ah Im (22 shared papers)Hope S. Rugo (30 shared papers)Stefan Michiels (31 shared papers)
- Journals
- Annals of Oncology (81 papers)Journal of Clinical Oncology (23 papers)Clinical Cancer Research (18 papers)JNCI Journal of the National Cancer Institute (14 papers)The Lancet Oncology (13 papers)
- Partner nations
- AustraliaUnited StatesBelgium
In The Last Decade
Sherene Loi
414 papers receiving 59.9k citations
Sherene Loi's Hit Papers
Peers
Comparison fields: 5 of 163
- Oncology 32.7k
- Cancer Research 13.9k
- Immunology 11.4k
- Pulmonary and Respiratory Medicine 14.2k
- Physiology 943
Countries citing papers authored by Sherene Loi
This map shows the geographic impact of Sherene Loi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherene Loi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherene Loi more than expected).
Fields of papers citing papers by Sherene Loi
This network shows the impact of papers produced by Sherene Loi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherene Loi. The network helps show where Sherene Loi may publish in the future.
Co-authors
The 25 scholars most cited alongside Sherene Loi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 424 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 3448 |
| 2 | The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 Hit paper breakdown → | 2014 | 2466 |
| 3 | Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis Hit paper breakdown → | 2006 | 1644 |
| 4 | Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Hit paper breakdown → | 2016 | 1457 |
| 5 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Hit paper breakdown → | 2020 | 1374 |
| 6 | Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 Hit paper breakdown → | 2013 | 1373 |
| 7 | Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2015 | 1299 |
| 8 | Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Hit paper breakdown → | 2014 | 1066 |
| 9 | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Hit paper breakdown → | 2021 | 993 |
| 10 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2019 | 971 |
| 11 | Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 966 |
| 12 | Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer Hit paper breakdown → | 2006 | 953 |
| 13 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer Hit paper breakdown → | 2018 | 948 |
| 14 | Consensus guidelines for the definition, detection and interpretation of immunogenic cell death Hit paper breakdown → | 2020 | 897 |
| 15 | CD4+ follicular helper T cell infiltration predicts breast cancer survival Hit paper breakdown → | 2013 | 885 |
| 16 | Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers Hit paper breakdown → | 2014 | 868 |
| 17 | Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis Hit paper breakdown → | 2018 | 805 |
| 18 | Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2022 | 791 |
| 19 | 2007 | 776 | |
| 20 | Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis Hit paper breakdown → | 2017 | 763 |
About Sherene Loi
Sherene Loi is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 424 papers that have together received 61.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (119 papers), HER2/EGFR in Cancer Research (80 papers), Advanced Breast Cancer Therapies (80 papers), Breast Cancer Treatment Studies (60 papers), Cancer Genomics and Diagnostics (50 papers), Immunotherapy and Immune Responses (49 papers), Cancer Cells and Metastasis (26 papers) and Immune Cell Function and Interaction (21 papers). The work is most often cited by research in Oncology (32.7k citations), Cancer Research (13.9k citations), Immunology (11.4k citations), Pulmonary and Respiratory Medicine (14.2k citations) and Physiology (943 citations). Sherene Loi has collaborated with scholars based in Australia, United States and Belgium. Frequent co-authors include Christos P. Sotiriou, Martine J Piccart, Hiroji Iwata, Roberto Salgado, Peter Savas, Seock‐Ah Im, Hope S. Rugo, Stefan Michiels, Fabrice André and Nicholas C. Turner. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research, JNCI Journal of the National Cancer Institute and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.